BACKGROUND: Cigarette smoking is a risk factor for cardiovascular disease. The present study addressed the effect of tobacco use on the formation of two eicosanoids, thromboxane A2 and prostacyclin, which have been implicated in both acute and chronic cardiovascular disorders. METHODS AND RESULTS: In 577 randomly sampled 18-19-year-old men, the urinary excretion of the 2,3-dinor metabolites of thromboxane A2 and prostacyclin (Tx-M and PGI-M, respectively) was analyzed and related to the subjects' self-reported use of tobacco. Sixty-five percent of the subjects used no tobacco, 7.5% were cigarette smokers, 22% used wet (oral) snuff, and the rest reported a mixed use of tobacco. The urinary excretion of Tx-M was higher (p less than 0.001) in cigarette smokers than in those not using tobacco (180 versus 128 pg/mg creatinine) and was correlated (r = 0.35, p less than 0.05) with the daily cigarette consumption. Snuff users had no increase in their urinary excretion of Tx-M, despite urinary cotinine levels comparable to those in the cigarette smokers (1,210 and 1,560 ng/ml, respectively). The excretion of PGI-M did not differ between non-tobacco users, cigarette smokers, and snuff users. CONCLUSIONS: We conclude that cigarette smoking, but not the use of snuff, facilitates the formation of thromboxane A2. We propose that such an increased formation reflects platelet activation in the absence of vascular injury and that it may be of significance for the subsequent development of cardiovascular disease.
BACKGROUND: Cigarette smoking is a risk factor for cardiovascular disease. The present study addressed the effect of tobacco use on the formation of two eicosanoids, thromboxaneA2 and prostacyclin, which have been implicated in both acute and chronic cardiovascular disorders. METHODS AND RESULTS: In 577 randomly sampled 18-19-year-old men, the urinary excretion of the 2,3-dinor metabolites of thromboxaneA2 and prostacyclin (Tx-M and PGI-M, respectively) was analyzed and related to the subjects' self-reported use of tobacco. Sixty-five percent of the subjects used no tobacco, 7.5% were cigarette smokers, 22% used wet (oral) snuff, and the rest reported a mixed use of tobacco. The urinary excretion of Tx-M was higher (p less than 0.001) in cigarette smokers than in those not using tobacco (180 versus 128 pg/mg creatinine) and was correlated (r = 0.35, p less than 0.05) with the daily cigarette consumption. Snuff users had no increase in their urinary excretion of Tx-M, despite urinary cotinine levels comparable to those in the cigarette smokers (1,210 and 1,560 ng/ml, respectively). The excretion of PGI-M did not differ between non-tobacco users, cigarette smokers, and snuff users. CONCLUSIONS: We conclude that cigarette smoking, but not the use of snuff, facilitates the formation of thromboxane A2. We propose that such an increased formation reflects platelet activation in the absence of vascular injury and that it may be of significance for the subsequent development of cardiovascular disease.
Authors: Přemysl Mladěnka; Lenka Applová; Jiří Patočka; Vera Marisa Costa; Fernando Remiao; Jana Pourová; Aleš Mladěnka; Jana Karlíčková; Luděk Jahodář; Marie Vopršalová; Kurt J Varner; Martin Štěrba Journal: Med Res Rev Date: 2018-01-05 Impact factor: 12.944
Authors: Jung Rae Cho; Bhaloo Desai; Michael J Haas; Fabiana Rollini; Francesco Franchi; Ana Muñiz-Lozano; Antonio Tello-Montoliu; Elisabetta Ferrante; Luis A Guzman; Theodore A Bass; Dominick J Angiolillo Journal: J Cardiovasc Transl Res Date: 2013-12-20 Impact factor: 4.132
Authors: Fabiana Rollini; Francesco Franchi; Jung Rae Cho; Christopher Degroat; Mona Bhatti; Elisabetta Ferrante; Ronakkumar Patel; Andrew Darlington; Antonio Tello-Montoliu; Bhaloo Desai; Joséluis Ferreiro; Ana Muniz-Lozano; Martin M Zenni; Luis A Guzman; Theodore A Bass; Dominick J Angiolillo Journal: J Cardiovasc Transl Res Date: 2014-01-07 Impact factor: 4.132
Authors: Michael S Boger; Aihua Bian; Ayumi Shintani; Ginger L Milne; Jason D Morrow; Husamettin Erdem; Valerie Mitchell; David W Haas; Todd Hulgan Journal: Antivir Ther Date: 2011-12-14
Authors: A Riutta; V Saareks; I Mucha; J Alanko; M Parviainen; H Vapaatalo Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1995-07 Impact factor: 3.000